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Background: This study was undertaken to explore the longitudinal patterns of health-related quality of life
(HRQoL) among youth and young adults with Hemophilia A (HA) over a 3-year period. This report presents the
baseline characteristics of the study cohort.
Methods: Males, 14 to 29 years of age, with predominantly severe HA were recruited from six treatment centres
in Canada. Subjects completed a comprehensive survey. HRQoL was measured using: the CHO-KLAT2.0 (youth),
Haemo-QoL-A (young adults) and the SF-36v2 (all).
Results: 13 youth (mean age = 15.7, range = 12.9-17.9 years) and 33 young adults (mean age = 23.6; range = 18.4
-28.7 years) with moderate (7 %) and severe (93 %) HA were enrolled. All were on a prophylactic regimen with
antihemophilic factor (Helixate FS®) during the study. The youth had minimal joint damage (mean HJHS = 5.2) compared
to young adults (mean HJHS = 13.3). The mean HRQoL scores for youth were: 79.2 (SD = 11.9) for the CHO-KLAT, and 53.0
(5.5) and 52.3 (6.8) for the SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) scores
respectively. The mean HRQoL scores for young adults were: 85.8 (9.5) for the Haemo-Qol-A, and 50.8 (6.4) and 50.9 (8.8)
for PCS and MCS respectively. PCS and MCS scores were comparable to published Canadian norms, however significant
differences were found for the domains of Physical Functioning and Bodily Pain. The disease-specific HRQoL scores were
weakly correlated with the PCS for youth (CHO-KLAT vs. PCS r = 0.28, p = 0.35); and moderately correlated for the MCS
(r = 0.39, p = 0.19). Haemo-QoL-A scores for young adults were strongly correlated with the PCS (r = 0.53, p = 0.001); and
weakly correlated with the MCS (r = 0.26, p= 0.13). Joint status as assessed by HJHS was correlated with PCS scores. A
history of lifelong prophylaxis resulted in better PCS but worse MCS scores.
Conclusion: Despite having hemophilia, the youth in this cohort have minimal joint disease and good HRQoL. The
young adults demonstrated more joint disease and slightly worse HRQoL in the domains of physical functioning and
pain. The data presented here provide new information to inform the selection of Health Related Quality of Life (HRQoL)
instruments for use in future clinical trials involving persons with hemophilia.
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Hemophilia A is a hereditary disorder resulting in deficient
levels of plasma coagulation factor VIII (FVIII) and lifelong
bleeding manifestations, particularly repeated hemarthroses
leading to permanent joint damage. Major progress has
been demonstrated in preventing bleeding and disability
when intensive factor replacement therapy is administered
prophylactically from an early age [1]. The objective assess-
ment of the outcome of different treatment strategies in
hemophilia is multidimensional and includes the measure-
ment of bleeding rates, joint and musculoskeletal status,
pain, physical functioning and social functioning based on
holistic models of health as recommended by the
WHO [2]. Health-related quality of life (HRQoL) tools
are self-administered questionnaires developed in order
to measure the perceived impact of a medical condition
and its treatment on a person’s physical, emotional and
social well-being.
In hemophilia both generic and disease-specific
HRQoL questionnaires have been used in recent years
although seldom simultaneously in the same subjects.
Recent clinical trials have incorporated the measurement
of HRQoL scores before and after an intervention such
as the introduction of a prophylactic factor replacement
regimen. However, there is very little published data on
long term longitudinal trends of HRQoL in hemophilia.
Significant variations in HRQoL may not be determined
only by change in physical status but may be influenced
by common social events such as educational, vocational
or relational changes associated with transition from
adolescence to adulthood.
We initiated a study in which HRQoL was assessed and
described prospectively every 6 months over a 3-year
period in a cohort of youth and young adults with severe or
moderate hemophilia A receiving routine care. This study
will enable the assessment of the relationship between
changes in HRQoL scores and changes in physical health
as evaluated by clinical assessments (bleeding frequency,
product utilization and joint scores). It will also enable us
to examine the sensitivity of the main HRQoL measures to
significant life events in patients with hemophilia. We
present in this report the baseline information on HRQoL
for the cohort of Canadian youth and young adults with
HA that were followed prospectively over a 3-year period.
Methods
Recruitment/Sample
To be included in the study subjects were required to be
males 14 to 29 years of age with moderate (FVIII level 0.02
– 0.05 U/ml) or severe HA (FVIII level < 0.02 U/ml) treated
with the recombinant antihemophilic factor Helixate FS®
either on a prophylactic or “on-demand” regimen. Subjects
were identified from the clinical records at six hemophilia
treatment centres in Canada, three in the province ofQuebec (Montreal and Quebec City) and three outside
(Edmonton, Toronto, Ottawa). Potential subjects were ex-
cluded if they had a current inhibitor to FVIII defined as an
inhibitor level of equal to or greater than 0.6 Bethesda
Units/mL, human immunodeficiency virus (HIV) infection
or symptomatic hepatitis C virus (HCV) infection. Informa-
tion on ethics approval and consent is provided in the
Declarations section below. Study funding was provided by
CSL Behring Canada. The study was registered in the Clini-
calTrials.gov database on December 17, 2009 under the
trial number: NCT01034904.
Measures/Manoeuvre
Chart review and demographic survey
The following baseline data was obtained by chart review:
severity of haemophilia, history of target joints in the
preceding year (defined as a joint with 3 or more bleeds in
3-month period), history of prior major bleeding events
requiring hospital admission (e.g. an intracranial hemorr
hage), previous surgery, current treatment program, and
any concomitant medical condition. Definitions of a target
joint and prophylaxis as stated in the protocol were based
on published Canadian consensus definitions [3]. Subjects
also completed a comprehensive demographic survey relat-
ing to educational and professional experience.
Health- related quality of life assessment
All subjects completed a generic and a disease-specific
HRQoL questionnaire at baseline.
The same generic questionnaire was used for all sub-
jects. The Medical Outcomes Study 36-item Short Form
health survey (SF-36) is an instrument that has been vali-
dated for a variety of diseases and has been widely used in
hemophilia. It has been normed for populations in several
countries and therefore allows comparisons with both
normal and diseased populations [4]. The 36 questions are
grouped to assess 8 domains of HRQoL with scores
ranging from 0 (worse) to 100 (best): Physical Functioning
(PF), Role Physical (RP), Bodily Pain (BP), General Health
(GH), Vitality (VT), Social Functioning (SF), Role Emotion
(RE) and Mental Health (MH). Furthermore, the Physical
Component Summary (PCS) and Mental Component
Summary (MSC) scores are derived from the 8 domains.
These are reported using norm-referenced scoring with a
mean of 50 and standard deviation of 10 points [5].
Subjects completed a different disease-specific HRQoL
questionnaire depending on their age. Youth aged 14 to
17 years completed the Canadian Haemophilia Outcomes
– Kids Life Assessment Tool (CHO-KLAT) version 2.0
[6–9], which was developed and validated for children and
adolescents with hemophilia. It consists of 35 questions
and is scored from 0 to 100.
In subjects 18 years and above the Haemo-QoL-A, devel-
oped by Rentz et al, was used [10]. It comprises 41 items
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(best): Physical Functioning, Role Functioning, Worry,
Consequences of Bleeding, Emotional Impact and Treat-
ment Concerns. This disease-specific instrument has also
been demonstrated to be reliable and valid for assessing
HRQoL in adult patients in hemophilia clinical trials [10].
Joint status assessment
A standardized physical examination of the joints most
commonly affected by hemophilia (the elbows, knees
and ankles) was performed by a trained physiotherapist
using the Hemophilia Joint Health Score (HJHS) version
2.0 [11–13]. This comprises an assessment of each of
these 6 joints with regards to swelling, muscle atrophy,
crepitus, range of motion, joint pain, strength, and global
gait. The score for each joint is summed to obtain a total
score ranging from 0 to 124, where no joint damage is
indicated by a score of 0. A total score above 10 has
been considered indicative of significant joint disease in
a published study of young adults [14].
Statistical analysis
Descriptive statistics were generated for the demographic,
clinical, and HRQoL measures. Frequencies and/or per-
centages (%) are reported for categorical data. Means and
standard deviations (SD) are presented for continuous
measures that are normally distributed. Medians and
ranges are presented for skewed data (skew or kurtosis ra-
tio > ±3.0). Benchmarks from the literature were included
to enable comparisons.
The scores from generic and disease specific HRQoL
measures were compared using Pearson correlations.
Pearson correlations were also used to examine the rela-
tionship between HRQoL and joint status as measured by
the HJHS. We interpreted the strength of each correlation
as recommended by Cohen, with a correlation of 0.1 indi-
cating a weak relationship, 0.3 to 0.5 indicating a moderate
relationship, and above 0.5 indicating a large or strong
relationship [15].
The relationships between disease characteristics, treat-
ment program, joint status and HRQoL were explored
using independent sample t-tests and analysis of variance
(ANOVA). The incremental impact of age on the PCS and
MCS SF-36 summary scores was tested via linear multiple
regression controlling for joint status as measured by the
HJHS. The minimally important difference (MID) threshold
for the SF-36 was used as the criterion for clinical signifi-
cance on this generic measure. MID’s are reported for the
PCS (2–3), MCS (3), PF (2–3), RP (2), BP (2–3), GH (2–3),
VT (2–3), SF (3), RE (4), and MH (3) [5]. Score differences
above the MID are considered meaningful. Minimal thresh-
olds for changes in scores that are clinically relevant have
not been defined for CHO-KLAT and Haemo-QoL-A.
Stata® version 13.0 was used to perform all analyses.Results
Forty-eight subjects were enrolled into this longitudinal
study however two subjects were excluded from the ana-
lysis due to incomplete data and withdrawal of consent.
The sample reported here included: 13 youth (mean age =
15.7, range = 12.9–17.9 years) and 33 young adults (mean
age = 23.6; range = 18.4–28.7 years). One 12.9 year-old
subject was included in the analysis. His recruitment was a
protocol deviation allowed by the investigators due to the
small number of youth in this study. The group included
43 patients with severe disease (93 %); as well as 2 youth
and one adult with moderate disease.
At recruitment, 15 % of the youth and 27 % of the
young adults were considered to have had an active target
joint in the prior year. Of these, 2 young adults had more
than one target joint. HJHS scores ranged from 0 to 17 in
the youth (mean = 5.2, standard deviation, SD = 5.61) and
0 to 34 in the young adults (mean = 13.3, SD = 8.93),
where no joint damage is indicated by a score of 0. Signifi-
cant joint disease (HJHS scores >10) was more common
among young adults (64 %) as compared to youth (23 %).
All subjects were on some form of prophylaxis at the
time of recruitment, which was defined as the regular
infusion of FVIII at least once weekly with the aim of pre-
venting clinically significant bleeding [3]. Although eligible,
no subjects on an “on demand” regimen were recruited
because of the paucity of patients on such a regimen in the
specified age group at the study sites. Ten subjects (8 youth
and 2 adults) were considered by the investigators to have
been on lifelong primary prophylaxis from early childhood
until the time they were recruited to the study. For the
purpose of this study, primary prophylaxis was defined as
prophylaxis that was started in a patient with no established
joint disease, usually in the first or second year of life, be-
fore a third bleed but usually after a first bleed [3]. In our
sample, 8 subjects (17.4 %) were currently on prophylaxis
one to two times per week, 21 (45.6 %) were on 3x/week or
alternate day prophylaxis and 17 (36.9 %) were on daily
prophylaxis. These details are summarized in Table 1.
The subjects were predominantly (83 %) from three cen-
tres in Quebec, a province where Helixate FS® was prefer-
entially prescribed for public tender contractual reasons.
Treatment protocols in this region do not differ in any
meaningful way from protocols elsewhere in Canada.
Subjects had a mean body mass index (BMI) of 25.1
(SD = 4.80) with a range of 18.4 to 37.9, which is similar to
the Canadian norm of 26.1 [16]. Based on 45 subjects with
complete BMI data, none of the subjects were under-
weight, 56 % of the subjects were of normal weight, 24 %
of them were overweight (BMI of 25 to 34.9) and 20 % of
study subjects were obese (BMI ≥ 35).
The group was diverse in terms of occupation. Of 46
subjects, 9 (20 %) were in occupations that were physically
demanding, 9 (20 %) were in jobs of relatively low physical
Table 1 Baseline sample characteristics
Study cohort youth Study cohort
young adults
Sample Size 13 33
Ages (years) Mean = 15.6 Mean = 23.6
SD = 1.4 SD = 2.9
Range: 12.9 to 17.9 Range: 18.4 to 28.7
Proportion with
Severe Haemophilia
85 % 97 %
Proportion with a Target Joint 15 % 27 %




a week = 15 %
Once or Twice
a week = 18 %
Alternate
Days = 54 %
Alternate
Days = 42 %
Daily = 31 % Daily = 39 %
HJHS Mean = 5.2 Mean = 13.3
SD = 5.6 SD = 8.9
Range: 0 to 17 Range: 0 to 34
St-Louis et al. BMC Hematology  (2016) 16:13 Page 4 of 9demand, and 27 (60 %) were students. Among the students,
14 were in secondary school, 9 were attending college or a
vocational school and 4 were attending university.
There were no major comorbidities in the study co-
hort. Seven patients had asymptomatic HCV. All other
concomitant medical conditions were of mild severity (2
patients had asthma, and one each with hypertension,
hypothyroidism and angioedema). One patient had a
major depression more than 5 years prior, and 7 were
considered to have suffered from attention deficit/hyper-
activity disorder during childhood.
HRQoL scores
Generic HRQoL scores (as measured by the SF36) were
available for the whole cohort of 46 subjects, including
the Component Summary scores (PCS and MCS), and
scores for the 8 domains. Disease specific HRQoL scores
were also available for the 13 youth (as measured by the
CHO-KLAT) and 33 young adults (as measured by the
Haemo-QoL-A).
In the combined cohort of 46 youth and young adults all
core variables met the distributional assumptions necessary
for parametric analyses. The PCS scores ranged from 35 to
63 with a mean of 51.4 (SD = 6.20), and MCS scores ranged
from 32 to 64 with a mean of 51.3 (SD = 8.23). Details for
the SF-36 results for youth and young adults are provided
in Table 2. This table shows the distributions of scores for
each group. Scores were slightly better in youth than in
young adults on all scales, as would be expected based on
the prevalence of target joints and arthropathy, with the
exception of Social Functioning. In order to compare to
published Canadian norms [17], we computed SF-36 scoresfor the sub-set of 27 subjects who were between the ages of
16 to 24.9 years at recruitment. These are presented on the
right side of Table 2; mean differences between this group
and the Canadian norms are also shown. When we exam-
ined the results in comparison to the Canadian norms,
Physical Functioning and Bodily Pain scores were signifi-
cantly worse in our hemophilia sample.
The CHO-KLAT scores for the youth ranged from 57.9
to 97.9 with a mean of 79.2 (SD = 11.86). The Haemo-QoL-
A scores for the young adults ranged from 65.9 to 98.1 with
a mean of 85.8 (SD = 9.54). Additional details of the
Haemo-QoL-A scores in our adult cohort are presented in
Table 3. This table also includes median scores from
Manco-Johnson et al. [18], who reported results for a
sample with a similar age range (all of whom were on
prophylaxis) from the United States, and mean scores from
Rentz et al. [10] based on an international sample of older
patients with a range of disease severity and comorbidity.
The overall Haemo-QoL-A scores in our cohort are similar
to the US cohort with the exception of higher (better)
scores for Treatment Concerns in the Canadians, and all of
our scale scores were significantly higher than those
reported by Rentz (p < 0.0001).
Relationships between HRQoL measures
The relationships between the generic and disease-
specific HRQoL scores were modest. The CHOK-LAT
scores for the 13 youth had a weak correlation with the
PCS (r = 0.28, p = 0.35), and moderate correlation with
the MCS (r = 0.39, p = 0.19). The Haemo-QoL-A scores
for the 33 young adults had a strong correlation with the
PCS (r = 0.53, p = 0.001) and a weak correlation with the
MCS (r = 0.26, p = 0.13). The lack of statistical signifi-
cance for some of these observed relationships may be
due in part to the small sample.
Relationships between target joints and HRQoL
The interpretation of HRQoL scores may be aided by an
understanding of how scores vary in relation to key clinical
characteristics. Therefore, we explored the relationship be-
tween HRQoL scores and the presence of a target joint.
There was a clinically meaningful difference in PCS
scores in the 11 subjects with one or more target joints
(mean = 49.1; SD = 6.32) compared to those without a
target joint (mean = 52.1; SD = 6.08). The MCS scores
were minimally lower in the 11 subjects with a target
joint (mean = 50.3; SD = 2.37) compared to those with-
out a target joint (mean = 51.6; SD = 1.43). A difference
of 3 points is considered clinically meaningful for the
component scores [5] Neither of these differences were
statistically significant (p = 0.18 and p = 0.66 respectively).
The Haemo-QoL-A scores did not reveal clinically mean-
ingful or statistically significant differences between those
with or without active target joints. We also explored the
Table 2 SF36 score distributions and comparisons to Canadian Norms
Means (standard deviations) Study Cohort Youth Study cohort
young adults
Study cohort comparative
sub-set (selected to match





Ages (years) 12.9 to 17.9 18.4 to 28.7 16 to 24.9 16 to 24.9
Sample Size 13 33 27 474
PCS (norm-referenced scoring) 53.00 50.79 51.74 53.9 2.16
(5.5) (6.4) (6.5) (6.9)
MCS (norm-referenced scoring) 52.3 50.9 51.1 49.3 -1.79
(6.8) (8.8) (8.6) (9.7)
Physical Functioning 90.0 87.1 87.9 93.6 5.64*
(10.4) (13.2) (13.7) (13.3)
Role Physical 86.1 84.1 84.5 89.9 5.41
(17.2) (13.9) (14.9) (27.1)
Bodily Pain 75.9 66.2 69.2 79.1 9.9*
(11.1) (19.4) (20.3) (19.4)
General Health 82.6 75.4 79.6 78.7 -0.93
(13.6) (15.5) (13.9) (14.7)
Vitality 71.2 64.9 65.7 64.0 -1.74
(10.4) (16.4) (16.9) (16.5)
Social Functioning 83.7 86.4 86.6 86.5 -0.07
(16.4) (12.6) (14.3) (18.7)
Role Emotional 89.7 85.1 86.7 82.7 -4.03
(14.5) (18.9) (17.5) (32.8)
Mental Health 80.4 77.1 77.2 74.3 -2.92
(9.9) (15.5) (15.2) (16.6)
MID’s definitions: PCS =2-3; MCS = 3; PF = 2-3; RP = 2; BP = 2-3; GH = 2-3; VT = 2-3; SF = 3; RE = 4; and MH = 3 [5]
*p < 0.05
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found no difference. We were unable to assess the differ-
ence in CHO-KLAT scores associated with target joints, as
there were only 2 youth with target joints.
Relationships between joint status and HRQoL
Next, we explored the relationship between HRQoL scores
relative to joint damage as measured by the HJHS. PCS
scores were strongly correlated with HJHS scores (r = -0.62,
p < 0.0001) in the combined sample (note: the correlations
were similar for both the youth and adult groups).
MCS scores had a weak correlation with HJHS scores
(r = 0.12, p = 0.42). HJHS total scores were weakly corre-
lated with both the CHO-KLAT scores in youth (r = -0.20,
p = 0.52) and the Haemo-QoL-A scores in adults (r = -0.19,
p = 0.28).
Relationships between treatment and HRQoL
Finally, we explored the HRQoL scores in groups with
different treatments. We began by looking specifically at
the 10 subjects (including 8 youth) who had been onprimary prophylaxis from early childhood compared to
the 36 subjects who had not. The PCS scores for the 8
youth on primary prophylaxis (mean = 53.5; SD = 5.54)
were only slightly higher than those for the 5 remaining
youth (mean = 52.3 SD = 5.91). However, the MCS scores
were worse for the youth on primary prophylaxis
(mean = 49.9; SD = 7.70) when compared to the others
(mean = 56.2; SD = 1.85). A similar trend was found for
the two adults on primary prophylaxis (mean PCS =
53.8 SD = 9.79 and mean MCS = 36.6 SD = 4.29) com-
pared to the 31 others (mean PCS = 50.6 SD = 6.35 and
mean MCS = 51.8 SD = 8.23).
When we combined youth and adult groups the mean
PCS for the primary prophylaxis group was 53.5 (SD =
5.87) vs. 50.83 (SD = 6.24) for the others, and the mean
MCS score for the primary prophylaxis group was 47.2
(SD = 8.90) vs 52.4 (SD = 7.80). Data for the combined sam-
ple are shown in Fig. 1, and may suggest that primary
prophylaxis is associated with better physical scores but
worse mental scores. It is worth noting that the group on
primary prophylaxis were younger by approximately 5 years,
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HJHS scores and all had severe hemophilia. We were not
able to examine the relationship between those on primary
prophylaxis with the disease-specific HRQoL scores be-
cause of small sample sizes.
SF-36 component summary scores were also examined
according to weekly frequency of prophylactic regimen at
the time of recruitment. In the combined cohort, the
mean PCS score for the 8 subjects on prophylaxis one to
two times per week was 53.6 (SD = 4.78). The 21 subjects
on prophylaxis 3 times per week or alternate days had a
mean PCS score of 52.4 (SD = 6.73). The 17 subjects
receiving daily prophylaxis had a mean PCS score of 49.1
(SD = 5.66). Mean MCS scores for these same groups were
48.3 (SD = 9.9), 52.6 (SD = 8.0), and 51.0 (SD = 7.83)
respectively.
Impact of age
It is known that in the general population HRQoL dimin-
ishes as a function of age [5]. We found a reduction of
0.31 points per year of age (p = 0.14) in the PCS scores,
and a decline by 0.33 per year (p = 0.25) in the MCS, but
neither reached statistical significance. The reduction of
scores as a function of age was also observed with the
disease-specific measures: CHO-KLAT scores decreasedby 0.73 points per year of age among the 13 youth
(p = 0.78); and Haemo-QoL-A scores decreased 1.01
points per year of age (p = 0.09) among the 33 young
adults.
Discussion
This paper reports the baseline data of a study with a
primary objective to describe the patterns of QoL over a
3-year period in Canadian youth and young adults who
have moderate or severe hemophilia A and who are
using Helixate FS®.
Forty-six subjects were recruited from 6 centres in 3
Canadian provinces but were predominantly from Quebec
because Helixate FS® is preferentially used in that province
for reasons of public tender contract. Although limited to
one brand of recombinant factor concentrate, there is no
reason to suspect that the product brand would have a
significant impact on HRQoL. This cohort comprised
subjects 12.9 to 28.7 years of age who were free from HIV
or other significant comorbid conditions.
We had a relatively small group of youth, most of whom
had been on prophylaxis from an early age, and a larger
group of young adults most of whom had not been intro-
duced to prophylaxis at an early age as is typical in Canada
for these age groups. While very frequently used in Canada,
prophylaxis is not universal in this age group and our
findings may not be applicable to patients who are “on-de-
mand”. There are no other recruitment criteria that would
differentiate this cohort, and it is therefore a small but
representative sample of Canadians with moderate or se-
vere HA. The subjects were unremarkable in terms of their
BMI scores. In our sample (mean age of 21.4 years), 52 %
had significant joint disease (HJHS > 10) which compares to
the slightly older Dutch cohort (mean age of 24.8 years)
described by Fischer et al. [14], in which 46 % had signifi-
cant joint disease.
Generic HRQoL scores
The main focus of this study was on the HRQoL of youth
and young adults with hemophilia which was captured
using both a generic (SF-36) and two disease-specific ques-
tionnaires; one for youth (CHO-KLAT) and one for adults
(Haemo-QoL-A). We began with an examination of the
SF36 component scores. When we compared the results of
our study subjects, between the ages of 16 to 24.9 years, to
published normative data for healthy Canadian males in the
same age range, we found that our mean scores were simi-
lar to the PCS and MCS norms. However, we found several
notable differences when we examined the 8 domains
within the SF-36 (see Table 2). Our cohort reported lower
scores compared to Canadian normative data in the follow-
ing domains: Physical Functioning (mean difference = 5.6),
Role Physical (5.4), and Bodily Pain (9.9). The differences















Fig. 1 SF36 Component Scores by Prophylaxis Type
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cant. These results are consistent with what one would
expect based on clinical experience. We also identified
areas of strengths in our cohort, with higher scores than
the norms in the following domains: Role Emotional (mean
difference = 4.0) and Mental Health (2.9). These differences
were not statistically significant.
Similar comparative analysis was conducted in Sweden,
by Lindvall et al. [19], who reported on a cross-sectional
study of severe HA subjects aged 15–34 years from a single
treatment center. They found that SF-36 PCS and MCS
scores were not statistically different than the national
norms, which is consistent with our findings. However, they
found significantly impaired HRQoL based on some of the
SF-36 domains (PF and PR), and for PCS scores only in
their older subjects (35 to 64 years). More intensive prophy-
laxis in Sweden than in Canada may explain the delay in
decline of HRQoL in that country.
We found significant differences in PCS but not MCS
scores related to joint status (HJHS) in our Canadian
cohort. However, PCS and MCS were not worse in those
reporting an active target joint in the preceding year,
suggesting that functional joint status more than bleed
frequency impacts HRQoL.
To explore the relationship of HRQoL to treatment
history we first compared the PCS and MCS scores in those
who had been on lifelong primary prophylaxis versus the
others. We found better PCS scores but worse MCS scores
in the primary prophylaxis group. These results should be
interpreted with caution given the small number of subjects
involved and the difference in age between the two categor-
ies of subjects. They are intriguing given that we identified
Role Emotional and Mental Health domains as areas of
strength in our hemophilia cohort compared to Canadiannorms. The exploration of HRQoL in relation to prophy-
laxis frequency found an inverse relationship, in that those
receiving the most frequent treatment (daily) had the low-
est PCS scores. However, there was no clear relationship
between frequency of treatment and MCS scores. These
mental health findings warrant investigation in future larger
studies.
When we explored age-related differences in the cross-
sectional cohort, we found that PCS and MCS scores
declined as a function of age in a similar fashion. However,
clinical experience suggests that the PCS scores should
decline to a greater extent than MCS, given the contribu-
tions of both the natural aging process and cumulative joint
damage associated with hemophilia. This requires further
examination in longitudinal studies.
Disease specific HRQoL scores
The analysis of the disease-specific results from this study
is limited due to the small sample sizes, particularly for
youth. The mean CHO-KLAT score in this cohort (79.2)
was somewhat higher than reported in previous studies
such as: the Canadian validation study 74.6 [9]; Quebec
validation study 71.9 [8]; and recent Toronto study 75.4
[20]. However, the scores are very close to the mean of
78.0 for a subset of 19 patients from the Toronto study
who were 14 years of age or older [20].
Although the mean Haemo-QoL-A total score found in
our young adults (85.8) appears high compared to the
Rentz et al. results [10], our adult cohort was much youn-
ger, had less viral co-morbidity and did not include a
significant proportion of subjects treated “on demand” (see
Table 3). Similarly, Ingerslev found much higher Haemo-
QoL-A total scores for Danish patients on prophylaxis (me-
dian score = 86.5) than in Russian patients that had been
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Johnson et al. [18] studied prospectively a cohort of severe
HA subjects also age 14-29 years who had mostly been on
prophylaxis. She reported a mean Haemo-QoL-A total
score of 85.6 (SD = 10.7) for a group of 22 subjects (with a
median age of 17 years) who had been on uninterrupted
prophylaxis at the time of study entry. The results from the
latter study are very similar to ours (Table 3).
Our data revealed modest correlations between disease
specific scores and the generic SF36. The CHO-KLAT
demonstrated a better relationship with the MCS than PCS
and the Haemo-QoL-A demonstrated a better relationship
with the PCS than MCS indicating again that they are not
assessing the same aspects of quality of life.
We have found that global scores are less sensitive than
subdomains in understanding HRQoL in severe hemophilia
as a decline in physical scales may be offset by mental
scores higher than normative data in this condition. The
areas of bodily pain and physical functioning deserve
particular attention when assessing differences in cohorts
or treatment approach. The lack of statistical correlation
between joint status and disease specific HRQoL scores
(CHO-KLAT and Haemo-QoL-A) may reflect differences
in the nature of the items included in these tools which
focus more on emotional health.
We were not surprised to see the subtle decline in
HRQoL as a function of age; this should be kept in mind
when comparing SF-36 and other instruments’ scores
between studies involving cohorts of different age groups.
The small sample size did not allow us to perform more
sophisticated analyses, therefore the relationship between
age, HJHS and HRQoL could not be fully assessed.
Conclusions
Despite having mostly severe hemophilia, the youth in this
cohort had minimal joint disease and good HRQoL. The
young adults demonstrated more joint disease and slightly
worse HRQoL – but were almost comparable to healthy
populations of the same age. These findings confirm those
of other investigators studying cohorts in developed coun-
tries and should now be expected in patients with access
to adequate levels of prophylaxis.
We also identified that primary prophylaxis was asso-
ciated with better PCS scores, which is consistent with
their younger age, lower prevalence of target joints and
better HJHS scores. However, this group also had lower
MCS scores which were atypical for their age group.
This requires further examination and potentially war-
rants more emotional health related questions be asked
of youth with a history of primary prophylaxis in clinical
practice.
Comparatively little is known about factors that might
influence longitudinal patterns of HRQoL in patients on
a stable treatment regimen. The current results form thefoundation for a longitudinal study to examine the im-
pact of biological factors and life events on the HRQoL
of youth and young adults with haemophilia followed
prospectively for 3 years.
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